H2 Equity Partners has sold Optegra to MidEuropa
Established in 2007, Optegra is a leading European ophthalmology platform headquartered in the UK and operating in Poland, the Czech Republic and Slovakia. Led by an experienced management team, it delivers best-in-class patient experience and achieves market-leading outcomes across the three focus areas of cataract, age-related macular degeneration and vision correction to both public and private pay patients. The platform operates out of 29 highly integrated, state-of-the-art facilities, performing more than 100,000 surgical procedures per year and has an increasing focus on public reimbursed cataract surgery given the growth dynamics in this clinical area globally.
Following H2 Equity Partners’ investment in early 2021, management has delivered on an impressive profit improvement and growth strategy and transitioned the company to a clinically focused true “platform”; with standardized pathways, protocols, systems and consumables, thereby laying the foundations for further accelerated geographic expansion. Since 2021, greenfield sites have been established in the UK, while M&A acquisitions have been executed across Poland, Czech Republic and Slovakia.
Lincoln International acted as the exclusive sell-side financial advisor, running a robust, bespoke process during a challenging macroeconomic environment. The Lincoln team worked closely with the shareholders and management team, designing the process to give bidders early access to a world-class management team and providing fulsome diligence materials to solidify interest within the buyer pool. Both corporate finance and debt advisory advice were provided by Lincoln, which proved critical as the debt markets deteriorated post the summer break, demonstrating the value of Lincoln’s integrated advisory approach. The deal ultimately completed with the sale to MidEuropa, with their investment set to support Optegra in delivering its business plan and utilizing both the UK greenfield and European M&A opportunities.
Matthew Lee, Managing Director and co-head of Lincoln’s European Healthcare Group, commented, “Optegra is ideally positioned for continued organic growth across its current footprint and expansion into new geographies. We are delighted to have advised H2 Equity Partners and the management team in achieving a successful outcome in what was a challenging market. This deal sets Optegra up for its exciting next chapter growth, and we are confident that Peter Byloos and his team, with MidEuropa’s experience in healthcare and expertise in Central and Eastern European markets, will over deliver their five-year business plan.”
Meet our Senior Team
I build trust with clients by putting their interests first at all times.
View More Transactions in Healthcare
Lincoln International advised Aquiline Capital Partners on the acquisition of Health Prime from GPB Capital Holdings
Lincoln International advised Talisman Capital Partners on the sale of ADVOCATE RCM to Ventra Health, a portfolio company of Varsity Healthcare Partners
Lincoln International advised Mars on the sale of Diamond Animal Health to Veterinary Pharmaceutical Solutions, a portfolio company of Granite Creek Capital Partners
Lincoln International advised 7Mind on its sale to Gymondo, a portfolio company of Oakley Capital
Lincoln International advised Olive AI on the sale of substantially all of its assets to Waystar and Humata Health
Lincoln International advised EQT on the acquisition of a controlling stake in Indira IVF from TA Associates and promoter family
Lincoln International advised Scantox Group, a portfolio company of Impilo, on its acquisition of QPS Austria’s Neuropharmacology Division
Lincoln International advised Seven Hills Capital on raising capital for Reliable Medical
Any information or testimonials contained in this post may not be representative of the experience of other clients and is no guarantee of future performance or success.